www.taro.com

Trademarks and Copyright© The images and information contained in the Site are, to the fullest extent possible, copyrighted and otherwise proprietary. It is the policy of Taro to enforce its intellectual property rights to the fullest extent of the law, including (where applicable) seeking criminal sanctions.


2004
 
DateTitle
12/27/2004
Taro Receives Approval for Hydrocortisone Butyrate Ointment, 0.1% ANDA
12/23/04
Taro to Supply Generic Elocon® Cream to Clay Park in U.S.
12/16/2004
Taro USA Receives Approval for Halobetasol Propionate Ointment, 0.05% ANDA; Company Also Receives Tentative Approval for Gabapentin Oral Solution, 250 mg/5 mL ANDA
12/6/04
Taro USA Receives Tentative Approval for Mometasone Furoate Topical Suspension USP, 0.1% (Lotion) ANDA
12/3/2004
Taro USA Receives Approval for Mometasone Furoate Ointment ANDA; Company Also Receives Tentative Approval for Mometasone Furoate Cream ANDA
11/22/2004
Taro Reports "A+" Bond Rating in Israel
10/28/2004
Taro Reports Third Quarter and Nine Month 2004 Results
10/26/2004
Taro to Report 3rd Quarter 2004 Results and Conduct Call on October 28, 2004
10/13/2004
Taro Announces Approvals of ANDAs for Betamethasone Dipropionate Ointment (Augmented) and Ciprofloxacin Tablets
10/1/2004
Taro Pharmaceutical Industries Reports Retirement of Aaron Levitt as President of the Company
8/20/2004
Taro Receives FDA Approval for Loratadine Syrup, 5 Mg / 5 mL ANDA
7/30/2004
Taro Receives FDA approval for Alclometasone Dipropionate Ointment USP, 0.05% ANDA
7/29/2004
Taro Receives Final Approval for Fluconazole Tablets ANDA

7/29/2004
Taro Receives FDA Approval for Clotrimazole and Betamethasone Dipropionate Lotion ANDA
7/29/2004
Taro Reports 2nd Quarter & Six-Month 2004 Results and Provides Update on Proprietary Drug Pipeline
7/27/2004
Taro to Report 2nd Quarter 2004 Results and Conduct Conference Call on July 29, 2004
6/1/2004
Taro Receives FDA Approval for Ammonium Lactate Lotion, 12% ANDA
4/29/2004
Taro Reports 1st Quarter 2004 Results
4/28/2004
Taro to Report 1st quarter 2004 Results
4/7/2004
Taro Receives Approval for Terconazole Vaginal Cream, 0.8% ANDA
3/8/2004
Taro Receives Approval for Phenytoin Oral suspension USP ANDA
2/17/2004
Taro Reports Record 2003 Results
2/13/2004
Taro to Report 4th Quarter and Full Year 2003 Results
1/8/2004
Taro Expands U.S. Distribution Capacity with Purchase of New Jersey Facility
1/8/2004
Taro Receives Approval for Children's ElixSuretm IB(Ibuprofen) Oral suspension NDA
Privacy Statement   |   Terms of Use   |   Safe Harbor Statement